Imatinib Completed Phase 1 Trials for Unspecified Adult Solid Tumor, Protocol Specific Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT00253565Imatinib Mesylate and Capecitabine in Treating Patients With Advanced Solid Tumors
NCT00084513Trastuzumab and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic HER2/Neu-Expressing Cancer